|
1
|
Hao J and Shao K: The epidemiology,
current status of management, challenge and future strategy for
esophageal cancer in China. China Oncol. 21:501–504. 2011.
|
|
2
|
Domper Arnal MJ, Ferrández Arenas Á and
Lanas Arbeloa Á: Esophageal cancer: Risk factors, screening and
endoscopic treatment in Western and Eastern countries. World J
Gastroenterol. 21:7933–7943. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Okada E, Ukawa S, Nakamura K, Hirata M,
Nagai A, Matsuda K, Ninomiya T, Kiyohara Y, Muto K, Kamatani Y, et
al: Demographic and lifestyle factors and survival among patients
with esophageal and gastric cancer: The Biobank Japan Project. J
Epidemiol. 27:(Suppl):. S29–S35. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xiang K and Fan Q: Progress in medication
treatment of esophageal cancer. World J Gastroenterol.
20:3482–3487. 2012.
|
|
5
|
National Comprehensive Cancer Network
(NCCN): NCCN. Fort Washington, PA; https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdfDecember
14–2009
|
|
6
|
Nakamura T, Takahashi M, Niigata R,
Yamashita K, Kume M, Hirai M and Yasui H: Changes in blood
concentrations of trace metals in cancer patients receiving
cisplatin-based chemotherapy. Biomed Rep. 5:737–744. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sun H, Qin TJ, Ruan ZP, Wang H and Ma Y:
Clinical study of vinorelbine combined with cisplatin in the
treatment of advanced esophageal cancer. Cancer Res Prevent
Treatment. 33:682–685. 2006.(In Chinese).
|
|
8
|
Chen J, He Y, Hu B, Ji CS, Hu CL and Fan
PS: Prognostic value of the ERCC1 and TS genetic polymorphisms in
advanced esophageal cancer treated with Cisplatin/fluorouracil
chemotherapy. Tumor. 4:314–321. 2010.
|
|
9
|
Ryu H, Song IC, Choi YS, Yun HJ, Jo DY,
Kim JM, Ko YB and Lee HJ: ERCC1 expression status predicts the
response and survival of patients with metastatic or recurrent
cervical cancer treated via platinum-based chemotherapy. Medicine
(Baltimore). 96:e94022017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Palomba G, Atzori F, Budroni M, Ombra M,
Cossu A, Sini M, Pusceddu V, Massidda B, Frau B and Notari F: ERCC1
polymorphisms as prognostic markers in T4 breast cancer patients
treated with platinum-based chemotherapy. J Transl Med. 12:2722014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ting S, Mairinger FD, Hager T, Welter S,
Eberhardt WE, Wohlschlaeger J, Schmid KW and Christoph DC: ERCC1,
MLH1, MSH2, MSH6, and βIII-tubulin: Resistance proteins associated
with response and outcome to platinum-based chemotherapy in
malignant pleural mesothelioma. Clin Lung Cancer. 14:558–567.e3.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen C, Wang F, Wang Z, Li C, Luo H, Liang
Y, An X, Shao J and Li Y: Polymorphisms in ERCC1 C8092A predict
progression-free survival in metastatic/recurrent nasopharyngeal
carcinoma treated with cisplatin-based chemotherapy. Cancer
Chemother Pharmacol. 72:315–322. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moxley KM, Benbrook DM, Queimado L, Zuna
RE, Thompson D, McCumber M, Premkumar P, Thavathiru E, Hines L and
Moore KN: The role of single nucleotide polymorphisms of the ERCC1
and MMS19 genes in predicting platinum-sensitivity,
progression-free and overall survival in advanced epithelial
ovarian cancer. Gynecol Oncol. 130:377–382. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kalikaki A, Kanaki M, Vassalou H,
Souglakos J, Voutsina A, Georgoulias V and Mavroudis D: DNA repair
gene polymorphisms predict favorable clinical outcome in advanced
non-small-cell lung cancer. Clin Lung Cancer. 10:118–123. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bradbury PA, Marshall AL, Kulke AH, et al:
Prognostic significance of nuclear excision (NER) and base excision
(BER) DNA repair gene polymorphisms in esophageal cancer. J Clin
Oncol (ASCO Annual Meeting). 25:25112007.
|
|
16
|
Shan B, He Y, Chen J, Li XQ, Ji CS, Hu CL
and Hu B: Clinical outcome of advanced esophageal cancer treated
with cisplatin influenced by ERCC1 gene polymorphism in peripheral
blood. Chin J Cancer Prevention Treatment. 18:1447–1450. 2010.
|
|
17
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC cancer staging manual. 7th edition.
Springer-Verlag; New York, NY; pp. 103–15. 2009
|
|
18
|
Rice TW, Blackstone EH and Rusch VW: 7th
edition of the AJCC cancer staging manual: Esophagus and
esophagogastric junction. Ann Surg Oncol. 17:1721–1724. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
National Cancer Institute (NCI): Common
Terminology Criteria for Adverse Events (CTCAE). Version 4.03.
https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdfJune
14–2010
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Polee MB, Hop WC, Kok TC, Eskens FA, van
der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Stoter G and van
der Gaast A: Prognostic factors for survival in patients with
advanced oesophageal cancer treated with cisplatin-based
combination chemotherapy. Br J Cancer. 89:2045–2050. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Seiwert TY, Wang X, Heitmann J,
Villegas-Bergazzi V, Sprott K, Finn S, O'Regan E, Farrow AD,
Weichselbaum RR, Lingen MW, et al: DNA repair biomarkers XPF and
phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced
head and neck cancer. PLoS One. 9:e1021122014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Benhamou S and Sarasin A: Variability in
nucleotide excision repair and cancer risk: A review. Mutat Res.
462:149–158. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Benhamou S and Sarasin A: ERCC2/XPD gene
polymorphisms and cancer risk. Mutagenesis. 17:463–469. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gregg SQ, Robinson AR and Niedernhofer LJ:
Physiological consequences of defects in ERCC1-XPF DNA repair
endonuclease. DNA Repair (Amst). 10:781–791. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tantraworasin A, Saeteng S,
Lertprasertsuke N, Arayawudhikul N, Kasemsarn C and Patumanond J:
The prognostic value of ERCC1 and RRM1 gene expression in
completely resected non-small cell lung cancer: Tumor recurrence
and overall survival. Cancer Manag Res. 5:327–336. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Reed E, Dabholkar M, Thornton K, Thompson
C, Yu JJ and Bostick-Bruton F: Evidence for in the appearance of
mRNAs of nucleotide excision repair genes, in human ovarian cancer
tissues. Oncol Rep. 7:1123–1128. 2000.PubMed/NCBI
|
|
30
|
Wood RD: DNA repair in eukaryotes. Annu
Rev Biochem. 65:135–167. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vogel U, Dybdahl M, Frentz G and Nexo BA:
DNA repair capacity: Inconsistency between effect of
over-expression of five NER genes and the correlation to mRNA
levels in primary lymphocytes. Mutat Res. 461:197–210. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang J, Zhou XQ, Li JY, Cheng JF, Zeng XN,
Li X and Liu P: Prognostic significance of ERCC1 expression in
postoperative patients with gastric cancer. Chin J Cancer Res.
26:323–330. 2014.PubMed/NCBI
|
|
33
|
Wang Y, Chen J, Li X, He Y, Hu B, Ji C and
Xu J: Genetic polymorphisms of ERCC1 and their effects on the
efficacy of cisplatin-based chemotherapy in advanced esophageal
carcinoma. Oncol Rep. 25:1047–1052. 2011.PubMed/NCBI
|
|
34
|
Kim M, Ku JH, Kwak C, Kim HH, Lee E, Keam
B, Kim TM, Heo DS, Lee SH and Moon KC: Predictive and prognostic
value of ribonucleotide reductase regulatory Subunit M1 and
excision repair Cross-complementation group 1 in advanced
urothelial carcinoma (UC) treated with first-line gemcitabine plus
platinum combination chemotherapy. PLoS One. 10:e01333712015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Frischknecht L, Meerang M, Soltermann A,
Stahel R, Moch H, Seifert B, Weder W and Opitz I: Importance of
excision repair cross-complementation group 1 and ribonucleotide
reductase M1 as prognostic biomarkers in malignant pleural
mesothelioma treated with platinum-based induction chemotherapy
followed by surgery. J Thorac Cardiovasc Surg. 149:1539–1546.e1.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schena M, Guarrera S, Buffoni L, Salvadori
A, Voglino F, Allione A, Pecorari G, Ruffini E, Garzino-Demo P,
Bustreo S, et al: DNA repair gene expression level in peripheral
blood and tumour tissue from non-small cell lung cancer and head
and neck squamous cell cancer patients. DNA Repair (Amst).
11:374–380. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hossain M, Banik NL and Ray SK:
Synergistic anti-cancer mechanisms of curcumin and paclitaxel for
growth inhibition of human brain tumor stem cells and LN18 and
U138MG cells. Neurochem Int. 61:1102–1113. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chao YK, Wu YC, Liu YH, Tseng CK, Chang
HK, Hsieh MJ, Chu Y and Liu HP: Distant nodal metastases from
intrathoracic esophageal squamous cell carcinoma: Characteristics
of long-term survivors after chemoradiotherapy. J Surg Oncol.
102:158–162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang X, Shen L, Li J, Li Y, Li J and Jin
M: A phase II trial of paclitaxel and cisplatin in patients with
advanced squamous-cell carcinoma of the esophagus. Am J Clin Oncol.
31:29–33. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yun T, Han JY, Lee JS, Choi HL, Kim HY,
Nam BH and Kim HT: Phase II study of weekly paclitaxel and
capecitabine in patients with metastatic or recurrent esophageal
squamous cell carcinoma. BMC Cancer. 11:3852011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Matsumoto H, Kubota H, Higashida M, Yoden
E, Hiratsuka J, Haruma K, Nakamura M and Hirai T: Docetaxel/TS-1
with radiation for unresectable squamous cell carcinoma of the
esophagus-a phase II trial. Anticancer Res. 34:3759–3763.
2014.PubMed/NCBI
|
|
42
|
Schnirer II, Komaki R, Yao JC, Swisher S,
Putnam J, Pisters PW, Roth JA and Ajani JA: Pilot study of
concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients
with carcinoma of the esophagus and gastroesophageal junction. Am J
Clin Oncol. 24:91–95. 2001. View Article : Google Scholar : PubMed/NCBI
|
